Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Private equity funds grab smaller slice of M&A deals

Fri, 28th Mar 2014 00:00

By Freya Berry

LONDON, March 28 (Reuters) - Buyout firms are finding itharder to take part in mergers and acquisitions as the lure ofstronger equity markets persuades more funds seeking to exitassets to try their luck with a public share sale or turn tocash-rich corporate buyers.

Private equity-backed mergers and acquisitions (M&A) fell byalmost a third to $55.2 billion from a year ago, Thomson Reutersquarterly data showed on Friday.

European private equity firms accounted for 8 percent of M&Adeals in the year to date, down from 10 percent from the sameperiod last year and the lowest since 2011, although the valueof private equity-backed deals did rise in the region.

"The bottom line is that in many sectors private equity isstruggling to compete with the public markets," said JamesSimpson, Head of Sponsor M&A at UBS. "Assets that wouldnaturally have come to private equity are going to IPO."

The MSCI World Price Index surged 24 percentlast year. That has brought a rash of companies to market asthey seek to capitalise on buoyant public interest, limiting thedeals available for buyout firms.

Private equity firms are also grappling with asset priceinflation.

Valuations have risen, partly due to a scarcity of assets,because of companies turning to IPOs, but also due to a growingamount of undeployed fund capital which leaves private equityfunds paying out more as they hunt for ways to spend cash.

A report by Bain & Company this month found that undeployedcapital, or dry powder, hit $1 trillion at the end of 2013,pushed up by investors seeking returns in a world of lowinterest rates.

"Multiples have gone up," Simpson said. "You have toacclimatise to paying bigger prices, and that takes a bit oftime."

As well as expensive assets, funds are also shying away fromcompetition with huge corporate cashpiles built up since thefinancial crisis.

Last year, GlaxoSmithKline scrapped a plan to sellits drinks businesses Lucozade and Ribena in an auction whichwould have included private equity firms when Japan's SuntoryBeverage & Food muscled in.

"Whilst (investors) would continue to say this is afantastic environment in which to exit businesses, it's actuallystill proving to be a challenging environment in which to deploynew capital," said Alasdair Warren, head of European FinancialSponsors Group at Goldman Sachs.

"The IPO markets are so strong and the multiples are sohigh, that it is very difficult for sponsors to compete."

But despite the squeeze, private equity firms are confidentthat the rush to IPO will not last forever.

"It is likely that the IPO markets will remain open for sometime but how long it will last is hard to tell," said LionelAssant, Senior Managing Director and European Head of PrivateEquity at Blackstone.

"Public markets rightly demand a proven management team anda clear strategy for growth from any company floating."

Goldman Sachs led the global rankings for M&A advisorbanks with a 46.3 percent market share, while JP Morgan was top for European deals with a 32.4 percent market share, thedata showed.

There have been 271 deals in Europe so far, an increase of6.7 percent year-on-year. But the value of transactionsincluding net debt has soared 24 percent to $12.9 billion overthe same period, the data showed. (Editing by Elaine Hardcastle)

More News
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more
4 Jan 2024 14:01

UK dividends calendar - next 7 days

Friday 5 January 
British Land Co PLCdividend payment date
Hill & Smith PLCdividend payment date
JD Sports Fashion PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Liontrust Asset Management PLCdividend payment date
Lok'n Store Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
RS Group PLCdividend payment date
Tate & Lyle PLCdividend payment date
Monday 8 January 
abrdn Equity Income Trust PLCdividend payment date
Intermediate Capital Group PLCdividend payment date
Tuesday 9 January 
no events scheduled 
Wednesday 10 January 
Assura PLCdividend payment date
Bellway PLCdividend payment date
Fidelity Special Values PLCdividend payment date
LXi REIT PLCdividend payment date
Severn Trent PLCdividend payment date
Volex PLCdividend payment date
Vp PLCdividend payment date
Thursday 11 January 
AJ Bell PLCex-dividend payment date
Ashtead Group PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
CMC Markets PLCdividend payment date
dotdigital Group PLCex-dividend payment date
Ecora Resources PLCex-dividend payment date
European Assets Trust PLCex-dividend payment date
Foresight Group Holdings Ltdex-dividend payment date
GSK PLCdividend payment date
ICG-Longbow Senior Secured UK Property Debt Investments Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
Keystone Positive Change Investment Trust PLCex-dividend payment date
LondonMetric Property PLCdividend payment date
Murray International Trust PLCex-dividend payment date
National Grid PLCdividend payment date
Primary Health Properties PLCex-dividend payment date
Sage Group PLCex-dividend payment date
Smiths News PLCex-dividend payment date
SSE PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
TR Property Investment Trust PLCdividend payment date
Walker Crips Group PLCex-dividend payment date
WH Smith PLCex-dividend payment date
Worldwide Healthcare Trust PLCdividend payment date
XPS Pensions Group PLCex-dividend payment date
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.